A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Clinical trial NCT04254783 · COMPLETED

Trial details

NCT number: NCT04254783
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Ulcerative Colitis (UC)Crohn's Disease

Start date: 2020-05-27
Primary completion: 2022-10-14
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.